SCHEMBL29940412

SCHEMBL29940412

NC(=O)C1CC1c1cncc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 3/20 0.43
FAAH O00519 3/20 0.40
AURKA O14965 1/20 0.40
LCK P06239 1/20 0.40
FYN P06241 1/20 0.40
IGF1R P08069 1/20 0.40
MET P08581 1/20 0.40
KIT P10721 1/20 0.40
FGFR2 P21802 1/20 0.40
EPHA2 P29317 1/20 0.40
LTK P29376 1/20 0.40
AXL P30530 1/20 0.40
FLT3 P36888 1/20 0.40
MST1R Q04912 1/20 0.40
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40
SMYD3 Q9H7B4 1/20 0.38
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29302360 1.00 SLC9A1 (0.43) SLC9A1FAAHAURKALCKFYN
SCHEMBL24737409 0.85 FFAR1 (0.47) SLC9A1HCAR2SMYD3CHRNB4CHRNA3
SCHEMBL28855849 0.81 SLC9A1 (0.49) SLC9A1FAAHAURKALCKFYN
SCHEMBL31355230 0.81 CYP11B2 (0.41) FAAHAURKALCKFYNIGF1R
SCHEMBL24737411 0.80 SLC6A4 (0.39) HCAR2
SCHEMBL31076190 0.78 GPR88 (0.39) SLC9A1FAAHHCAR2CYP3A4
SCHEMBL29302480 0.77 TDP1 (0.41)
SCHEMBL29940167 0.77 TDP1 (0.41)
SCHEMBL24737580 0.75 SLC9A1 (0.71) SLC9A1
SCHEMBL15540612 0.75 SLC9A1 (0.71) SLC9A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4585265-A2 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2025-07-16 EP disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
EP-4308229-A1 INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2024-01-24 EP disclosed
CN-117396469-A Inhibitors of plasma kallikrein 武田药品工业株式会社 2024-01-12 CN disclosed
WO-2022197763-A1 INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 SLC9A1 4428/4885FAAH 721/4885AURKA 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.